Abstract
The pharmacokinetics of LB20304 was investigated following intravenous (IV) and oral administration to rats and dogs. Additionally,in vitro metabolism and serum protein binding studies were also conducted. The total body clearance, apparent volume of distribution, terminal half-life, and extent of bioavailability were 21.8 ml/min/kg, 2265 ml/kg, 93.6 min, and 30.8% for rats; and 7.95 ml/min/kg, 4144 ml/kg, 363 min, and 81.1% for dogs, respectively. LB20304 was stable in the liver microsome containing NADPH generating system and its serum protein binding was 58.5–65.8% for rats, 19.1–26.6% for dogs, and 56.9–59.6% for humans. Its tissue concentration levels in liver, stomach, small intestine, and kidney were 9.5 to 26.1 times greater than plasma level, but the concentration in testis was quite low and that in brain was negligible in rats. The 48 hr urinary recovery of the dose was 44% for IV dosing and 14% for oral dosing, whereas the 48 hr biliary recovery of the dose was 6.4% for IV dosing and 4.5% for oral dosing in rats. In summary, the pharmacokinetic properties of LB20304 were characterized by its good oral absorption, long plasma half-life, and good tissue distribution.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Blumberg, H.M., Rimland, D., Caroll, D.J., Terry, P. and Wachsmuth, I.K., Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistantStaphylococcus aureus.J. Infect. Dis., 163, 1279–1285 (1991).
Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal. Biochem., 72, 248–54 (1976).
Chiou, W.L., Critical evaluation of potential error in pharmacokinetic studies using the linear trapeizoidal rule method for the calculation of the area under the plasma level-time curve.J. Pharmacokin. Biopharm., 6, 539–546 (1978).
Czygan, P., Greim, H., Garro, A.J., Hutterer, F., Schaffner, F., Popper, H., Rosenthal, O. and Cooper, D.Y., Microsomal metabolism of dimethylnitrosamine and the cytochrome P-450 dependency of its activation to a mutagen.Cancer Res., 33, 2983–2986 (1973).
Dragnev, K.H., Beebe, L.E., Jones, C.R., Fox, S.D., Thomas, P.E., Nims, R.W. and Lubet, R.A., Subchronic dietary exposure to aroclor 1254 in rats: accumulation of PCBs in liver, blood, and adipose tissue and its relationship to induction of various hepatic drug-metabolizing enzymes.Toxicol. Appl. Pharmacol., 125, 111–122 (1994).
Fuchs, P.C., Barry, A.L., Pfaller, M.A., Allen, S.D. and Gerlach, E.H., Multicenter evaluation of thein vitro activities of three new quinolones, sparfloxacin, CI-960, and PD-131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.Antimicrob. Agents Chermother., 35, 764–766 (1991).
Fujii, T., Furukawa, H., Yoshida, K., Miyazaki, H. and Hashimoto, M., Disposition and metabolism of [14C]AT-2266 I. Single administration.Chemotherapy, 32, 117–135 (1984).
Gibaldi, M. and Perrier, D.,Pharmacokinetics. 2nd ed., Marcel Dekker, New York (1982).
Gilfillan, E.C., Pelak, B.A., Bland, J.A., Malatesta, P.F. and Gadebusch, H.H., Pharmacokinetic studies of norfloxacin in laboratory animals.Chemotherapy, 30, 288–296 (1984).
Jones, R.N., Fluoroquinolone resistance, an evolving national problem or just a problem for some physician?Diag. Microbial. Infect. Dis., 15, 177–179 (1992).
Kaatz, G.W., Seo, S.M. and Ruble, C.A., Mechanisms of fluoroquinolone resistance inStaphylococcus aureus.J. Infect. Dis., 163, 1080–1086 (1991).
Kasajima, H., Ishikawa, N., Machida, M., Uchida, H. and Irikura, T., Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys.Antimicrob. Agents Chermother., 30, 304–309 (1986).
Kim, M.Y., Oh, J.I., Paek, K.S., Hong, C.Y., Kim, I.C. and Kwak, J.H.,In vitro activities of LB20304, a new fluoroquinolone.Arch. Pharm. Res., 19, 52–59 (1996).
Montay, G., Goueffon, Y. and Roquet, F., Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.Antimicrob. Agents Chermother., 25, 463–472 (1984).
Nakamura, S., Kurobe, N., Ohue, T., Hashimoto, M. and Shimizu, M., Pharmacokinetics of a novel quinolone AT-4140 in animals.Antimicrob. Agents Chemother., 34, 89–441 (1990).
Oh, J.I., Paek, K.S., Ahn, M.J., Kim, M.Y., Hong, C.Y., Kim, I.C. and Kwak, J.H.,In vitro andin vivo evaluations of LB20304, a new fluoroquinolone.Antimicrob.Agents Chemother., 40, 1564–1568 (1996).
Okazaki, O., Kuruta, T., Hashimoto, K., Sudo, K., Tsumura, M. and Tachizawa, H., Metabolic disposition of DL-8280 the second report: absorption, distribution, and excretion of [14C]-DL-8280 in various animal species.Chemotherapy, 32, 1185–1202 (1984).
Okezaki, E., Terasaki, T. and Nakamura, M. Serum protein binding of lomefloxacin, a new antimicrobial agent, and its related quinolones.J. Pharm. Sci., 78, 504–507 (1989).
Ooie, T., Suzuki, H., Terasaki, T. and Sugiyama, Y., Characterization of the transport properties of a quinolone antibiotic, fleroxacin, in rat choroid plexus.Pharm. Res., 13, 523–527 (1996).
Piddock, L.J.B., New quinolones and gram-positive bacteria.Antimicrob. Agents Chermother., 38, 163–169 (1994).
Raviglione, M.C., Boyle, J.F., Mariuz, P., PablosMendez, A., Cotes, H. and Merlo, A., Ciprofloxacin-resistant methicillin-resistantStaphylococcus aureus in an acute-care hospital.Antimicrob.Agents Chemother., 34, 2050–2054 (1990).
Sato, K., Hosino, K., Tanaka, M., Hayakawa, I. and Osada, Y., Antimicrobial activity of DU-6859a, a new potent fluoroquinolone, against clinical isolates.Antimicrob. Agents Chermother., 36, 1491–1498 (1992).
Siefert, H.M., Maruhn, D. and Scholl, H., Pharmacokinetics of ciprofloxacin 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C] ciprofloxacin in albino rats.Arzneim. Forsch./ Drug Res., 36, 1503–1510 (1986a).
Siefert, H.M., Maruhn, D., Maul, W., Forster, D. and Ritter, W., Pharmacokinetics of ciprofloxacin 1nd communication: absorption, concentrations in plasma, metabolism, and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.Arzneim. Forsch./Drug Res., 36, 1496–1502 (1986b).
Sugino, A., Peebles, C.L., Kruezer, K.N. and Cozzarelli, N.R., Mechanism of action of nalidixic acid: purification ofEscherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.Proc. Natl. Acad. Sci. USA, 74, 4767–4771 (1977).
Thys, J.P., Jacobs, F. and Motte, S., Quinolones in the treatment of lower respiratory tract infections.Rev. Infect. Dis., 11 (Suppl. 5), S1212-S1219 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seo, MK., Lee, SH., Choi, YJ. et al. Pharmacokinetics of LB20304, a new fluoroquinolone, in rats and dogs. Arch. Pharm. Res. 19, 359–367 (1996). https://doi.org/10.1007/BF02976379
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976379